A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148) (COXIBUS)

Organon

Status: Completed

Conditions: Osteoarthritis

Treatments: Drug: celecoxib; Drug: etorocoxib

Study type: Observational

Funder types: Industry

Identifiers

NCT01572675

0663-148

Details and patient eligibility

About

This postmarketing study will examine the use of etoricoxib (Arcoxia®) in routine clinical practice in France as well as the use of celecoxib (Celebrex®).

Enrollment: 547 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Treatment-naive, discontinued the previous treatment course of etoricoxib or celecoxib at least 3 months previously or currently receiving continuous treatment with oral etoricoxib or celecoxib
• Consent to take part in the study
• Included in his/her physician's client base for at least 1 year

Exclusion criteria

• Unable to receive follow-up over a year
• Included in an interventional trial

Trial design

547 participants in 2 patient groups

Group Arcoxia®

Description:

Participants who were either previously treated with Arcoxia® or initiated on study treatment with Arcoxia®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.

Treatment:

Drug: etorocoxib

Group Celebrex®

Description:

Participants who were either previously treated with Celebrex® or initiated on study treatment with Celebrex®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.

Treatment:

Drug: celecoxib